Background: To evaluate whether tumor markers can be used to assess response to systemic chemotherapy, we analyzed preliminarily the relationship between the response to chemotherapy based on serial imaging and on change in serum tumor marker level of CEA, CA19-9 and CA125. Methods: We analyzed 26 patients with advanced gastric cancer in whom at least one of the tumor markers CEA, CA19-9 and CA125 was elevated before systemic chemotherapy with regard to the relationship between the change in serum tumor marker level and response assessment by imaging studies throughout the treatment course. A responder was defined as showing a~50% drop in tumor marker level for more than 4 weeks. Results: The sensitivity and negative predictive value of falling tumor marker level after chemotherapy for a partial response in imaging was 100 % • When patients were categorized as responders or non-responders, a significant correlation was observed between the assessment of response by tumor markers and by imaging studies. The survival time of responders assessed by tumor markers was significantly longer than that of non-responders.
INTRODUCTION
Chemotherapy for patients with unresectable or metastatic gastric cancer is still under investigation. However, some recent clinical trials which compared systemic chemotherapy with supportive care alone have revealed a significant benefit in survival and quality of life for patients treated with systemic chemotherapy (1) (2) (3) . At the present, the only drugs active against advanced gastric cancer are 5-fluorouracil, mitomycin-C, doxorubicin, cis-platinum and newly developed irinotecan, although various combination chemotherapies have been investigated to increase the anti-tumor activity (4) (5) (6) .
In the clinical practice of chemotherapy against neoplasm, the assessment of clinical efficacy is very important, because the decision to continue or discontinue treatment is based on it. In general, the assessment of response to chemotherapy of various solid tumors including advanced gastric cancer is made by measurement of tumor visualized by serial imaging, commonly CT scanning (7) . In addition, in Japan, X-ray series and endoscopy of the stomach are used for the assessment of the response to chemotherapy in the primary gastric lesion according to the criteria described in the general rules for the treatment of gastric cancer proposed by the Japan Society for Gastric Cancer (8) . However, objective assessment of efficacy in chemotherapy based on imaging is not always easy because patients often have a disease which is not measurable by imaging study, such as diffuse peritoneal dissemination in advanced gastric cancer. Furthermore, response assessment by imaging study is expensive and time consuming for the patients.
Recently, various tumors markers have been developed and it is known that the serum levels of markers such as carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CAI9-9) and carbohydrate antigen 125 (CA125) are elevated in patients with advanced gastric cancer (9) (10) (11) . However, the clinical usefulness of tumor markers has not been well defined from a diagnostic and therapeutic point of view. Tumor markers are not useful in diagnosis or screening disease because of low sensitivity and specificity. Although reports have shown the Jpn J Clin OncoI1999;29 (11) 551 value of tumor markers as a prognostic factor for patients with advanced gastric cancer, clinical studies evaluating the roles of tumor markers in the monitoring of chemotherapeutic efficacy are limited (12) (13) (14) (15) .
In the present study, we analyzed the relationship between conventional assessment of response to chemotherapy by serial imaging and that by the change in serum level of CEA, CA 19-9 and CA125, tumor markers commonly used in cases of advanced gastric cancer, in order to evaluate preliminarily whether tumor markers can be used to assess chemotherapeutic efficacy.
PATIENTS AND METHODS

PATIENTS
Between January 1997 and June 1998, a total of 31 patients with unresectable or metastatic gastric cancer with measurable lesion were treated with systemic chemotherapy in the Cancer Institute Hospital, Tokyo. In 28 of these 31 patients (90%), the pretreatment serum level of at least one of CEA, CA19-9 and CA125 was elevated. In 26 patients, the serial serum tumor marker level was measured and chemotherapeutic response was assessed by serial imaging studies throughout the course of the chemotherapy. Two patients were excluded because their tumor marker measurements were insufficient for analysis. The characteristics of the remaining 26 patients are summarized in Table 1 . Fifteen patients were male and 11 female and the median age was 51 years (range 35-76 years). The majority of patients had good performance status (PS 0 or 1 in 22 patients and PS 2 in four patients) and the functions of the main organs such as bone marrow, liver and kidney were well preserved prior to chemotherapy in all patients. Twentythree patients had no prior chemotherapy and three were previously treated with 5FU-based chemotherapy. The metastatic site was peritoneum in 12 subjects, lymph node in 11, liver in five, bone in three and lung in one. The chemotherapy regimens used in this period are listed in Table 2 .
MEASUREMENT OF TuMOR MARKERS Serum CEA, CA19-9 and CA125 levels were measured prior to initiation of chemotherapy (within 7 days) and then again every 2 weeks after initiation of chemotherapy. Serum CEA, CA19-9 and CA125 levels were measured by the enzyme immunoassay using an AxSYM CEA kit (Dainabot, Tokyo, Japan), Graozyme New CA19-9 kit (Wako Junyaku Kogyo, Osaka, Japan) and AxSYM CA125 kit (Dainabot, Tokyo), respectively. The cut-off values for CEA, CA19-9 and CA125 were 5.0 ng/ml 37 Uzrnl and 36 Urrnl, respectively.
ASSESSMENT OF CHEMOTHERAPEUTIC RESPONSE BY CHANGE OF TuMOR MARKER LEVEL
The assessment of response to chemotherapy was based on the change of individual markers and overall response on the combined assessment of multiple markers. The assessment of response to chemotherapy of each tumor marker was defined as follows. A complete response in tumor marker (CR-m) was defined as a drop to within the normal range of marker after chemotherapy for at least 4 weeks. A partial response in tumor marker (PR-m) was defined as a~50% reduction in level prior to chemotherapy for at least 4 weeks. No change in tumor marker (NC-m) was defined as a <50% reduction or <50% increase in the tumor marker level for at least 4 weeks. Progressive disease in tumor marker (PD-m) was defined as a >50% increase in level. The assessment of overall response based on combined multiple tumor markers was defined as follows. Overall CR-m was when CR-m was achieved for all markers. Overall PR-m was defined as PR-m achieved for all markers. A combination of CR-m and PR-m was defined as overall PR-m. Overall PD-m was when at least one of three markers was assessed as PD-m. All other situations were defined as overall NC-m.
ASSESSMENT OF CHEMOTHERAPEUTIC RESPONSE BY IMAGING
Imaging studies were performed prior to and every 4 weeks after the initiation of chemotherapy by using the technique employed for baseline tumor measurement, which included computed tomography and chest X-ray. For those patients with measurable lesions, responses were evaluated according to the World Health Organization (WHO) criteria (15) . A complete response (CR) was defined as the disappearance of all evidence of cancer for at least 4 weeks. A partial response (PR) was defined as a~50% reduction in the sum of the products of the perpendicular diameters of all lesions for at least 4 weeks, without any evidence of the development of new lesions or of the progression of any lesions. No change (NC) was defined as a <50% reduction or <25% increase in the sum of the products of the perpendicular diameters of all lesions, without any evidence of new lesions. Progressive disease (PD) was defined as a >25% increase in one or more lesions or the appearance of new lesions. Since there are no criteria for assessment of response in primary gastric tumor in the WHO criteria, the response of primary gastric lesion was evaluated according to 
STATISTICAL ANALYSIS
The correlation of assessment of efficacy by tumor markers and by imaging studies was analyzed using the chi-squared test. Survival curves were drawn using the Kaplan-Meier method and analyzed by the log rank test. Comparisons between unpaired groups were made using the Mann-Whitney U-test and correlations assessed using the Spearman rank order correlation. Results were considered significant if the p value was <0.05.
RESULTS
In 26 patients, the pretreatment serum CEA, CA19-9 and CAl25 values were elevated beyond the normal cut-off value in 14 (54%), 11 (42%) and 17 (65%) patients, respectively. The number of patients in which levels were elevated for a single marker of CEA, CA19-9 and CA125 was four, three and six, respectively. Half of the patients (13 patients) had more than two elevated markers. The combination patterns of elevated markers are summarized in Table 1 . The median value and the range of pretreatment CEA, CA19-9 and CA125 were 34.0 (5.5-2028) ng/ml, 163 (53.8-873.5) Vim I and 140.7 (42.5-577) Uzml, respectively. There was no correlation between an elevated marker and site of metastatic disease. In the subpopulation of patients who had more than two elevated markers prior to chemotherapy, there was a moderate correlation between the level of CEA and CA19-9 or CA125 (Spearman p =0.20,p =0.14).
The correlation between overall assessment of response by tumor markers and imaging studies is summarized in Table 3 . Overall CR-m and PR-m were achieved in seven (27%) and five patients (19%), respectively, and the response rate by tumor marker assessment was 46.1 %. The median period from initiation of chemotherapy to drop in tumor marker level by <50% was 43 days (range 9-77 days). Eight PRs (31%) were achieved by imaging studies but there were no CRs by imaging. Agreement in assessment by tumor markers and imaging study was observed in 11 patients (42%). However, when patients were categorized as responders (CR and PR or CR-m and PR-m) or non-responders (NC and PD or NC-m and PD-m), a significant correlation was observed between the assessment of response by tumor markers and by imaging (p = 0.0012; chi-squared test). There was no significant difference in clinicopathological features and baseline value of each tumor marker between the responders and non-responders (data not shown).
Comparisons of response assessment by tumor markers with that by imaging are shown in Tables 4 and 5 . A fall in any of the markers (CR-m and PR-m) was highly sensitive in the prediction of a partial response (PR) in the imaging study (100% sensitivity for all three markers). However, specificity was lower with a positive predictive value of 50% for fall in CEA, 60% for fall in CA 19-9 and 22% for fall in CA 125. The negative predictive value of drop in marker level for partial response was 100% for all three markers. Assessment by multiple markers improved the specificity and positive predictive value with sensitivity and negative predictive value remaining the same. The diagnostic accuracy of markers in predicting PR in imaging study was 73% (19/26) using three markers in combination, while it was as high as 82% (9/11) using CA19-9. (Table 4 ) Considering the prediction of progressive disease (PD) in the imaging study, the sensitivity of rising marker levels was 50% for CEA, 66% for CA 19-9 and 40% for CA125. The specificity was 100% for CEA, 88% for CA19-9 and 75% for CA125, higher than the sensitivity in each case, resulting in a high negative predictive value, 92% for CEA, 88% for CA19-9 and 75% for CA125. Assessment by multiple markers improved the sensitivity (80%) in the prediction of progressive disease. The diagnostic accuracy of markers in predicting PD in the imaging study was 81% (21/ 26) using three markers in combination, while it reached up to 93% (13/14) in CEA ( Table 5) .
The median survival time of all 26 patients was 225 days and the 1 year survival rate was 20%. Fig. 1 compares the survival times for responders (CR-m and PR-m) and non-responders (NC-m and PD-m) defined by efficacy assessment by tumor marker. A significant difference in survival was observed between responders and non-responders (p = 0.0056; log rank test) with a median survival time of 301 versus 127 days.
DISCUSSION
The WHO criteria are commonly used to assess therapeutic efficacy in the treatment of solid tumors. Criteria for assessing the response to chemotherapy based on the objective tumor shrinkage are essential for clinical trials to select and develop new anti-tumor agents. The RECIST criteria, which are a newly revised version of the WHO criteria, is also based on the objective tumor shrinkage. A 'measurable' lesion is required to assess the objective response and tumor markers alone cannot be used to assess response in such situations. However, in daily clinical practice of oncology, patients do not always have a 'measurable' lesion. Clinicians sometimes have to evaluate the tumor response based on a subjective medical judgement from clinical symptoms and laboratory data.
It is known that the serum levels of various tumor markers such as CEA, CAI9-9, CA12S and others are elevated in patients with gastrointestinal cancers. However, the clinical use of such markers in the management of these patients still remains controversial (13, 14) . Elevated CEA, CA19-9 and CA 125 levels have been reported in around 30-60% of patients with advanced gastric cancer and our results were also within this range (8) (9) (10) . Although the positive rate of each tumor marker was around 50%, in 90% (28 out of 31) of the patients who received systemic chemotherapy, the level of at least one of the tumor markers CEA, CA19-9 and CA12S was elevated. It is well known that elevated marker levels decrease after curative resection of tumor only to elevate again on recurrence (19, 20) . We therefore postulated that the change in these tumor markers would reflect the relative tumor burden in individual patients after chemotherapy when the marker levels had been elevated prior to chemotherapy. We analyzed here the serial change in tumor marker values from the viewpoint of chemotherapeutic response. Although the number of patients evaluated here was too small to confirm the reliability of the response assessment to chemotherapy based on serial change of tumor marker level, the results suggest the clinical usefulness of tumor markers in the monitoring of chemotherapeutic efficacy which enables us to distinguish clearly between responders and non-responders.
In the prediction of partial response, the sensitivity and negative predictive values of falling tumor marker levels were 100% for all three markers and tumor shrinkage always accompanied a drop in marker levels in the present study. In contrast to the high sensitivity of the three markers for prediction of tumor shrinkage, the specificity and positive predictive value of single markers was low. Additionally, the sensitivity of each marker for the prediction of progressive disease was also low. These observations seem to be due to the heterogeneity of tumor cells in individual patients and the assessment of migration between PR and NC in patients with falling marker levels and between NC and PD in patients with rising levels. Hence it should be kept in mind that both overestimation of tumor response and underestimation of progressive disease can occur when the chemotherapeutic efficacy is assessed by change in tumor marker level. As regards the overestimation of responses, this is perhaps explicable on the basis that the treatment had a significant inhibitory effect on the tumor which was insufficient to result in a response on imaging. The underestimation of disease progression, i.e. disease progression without rise in marker level, is a serious problem in clinical practice and is probably due to the heterogeneity of tumor cells.
CEA, CA19-9 and CA12S combined were elevated in a variety of patterns in the patients studied. Interestingly, when more than two markers were elevated, changes did not always occur in synchrony. This observation may reflect in part the biological heterogeneity of tumor cells and the heterogeneity of responsiveness to chemotherapy in the same patient. Concerning the diagnostic accuracy, CA19-9 was the most reliable marker for the prediction of PR (82%) and CEA for the prediction for PD (93%). However, CAl2S was less reliable in the prediction of clinical response in imaging than CEA and CAI9-9. In clinical practice, one should select the most useful marker from the viewpoint of cost effectiveness when the patient is positive for multiple markers. We recommend that one of CEA and CA 19-9 should be measured when both markers are increased before treatment.
The responders to chemotherapy showed falling tumor marker levels in the early period from initiation of treatment. The median interval between initiation of treatment and 50% decrease in tumor marker was 43 days (range 9-77 days). In addition, a fall in tumor marker level was significantly associated with survival of the patients. Falling tumor marker levels may be an early predictor of long-term survival in patients treated with systemic chemotherapy.
The nunber of patients analyzed here is very small and it is clear that tumor markers cannot replace the use of imaging in the management and assessment of patients with advanced gastric cancer treated with systemic chemotherapy, especially in clinical trials to evaluate anti-tumor activity. However, the present study suggests that tumor markers may be sensitive and useful for monitoring the response to chemotherapy and can be used to assess chemotherapeutic efficacy in daily clinical practice. In those cases in which disease is difficult to evaluate by imaging study, such as diffuse peritoneal dissemination, tumor markers may be used as a helpful means of monitoring chemotherapeutic efficacy. When these findings are confirmed by the analysis with a large sample size, the assessment of chemotherapeutic efficacy by tumor markers will provide benefits in cost and convenience.
In conclusion, the measurement of tumor markers might be useful in the monitoring of response and in the prediction of prognosis in patients with advanced gastric cancer treated with systemic chemotherapy. Further studies are required to confirm these findings.
